Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY16 Outlook
Get Alerts JNJ Hot Sheet
Price: $149.56 +0.30%
Revenue Growth %: -13.4%
Financial Fact:
Sales to customers (Note 9): 17.82B
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: -13.4%
Financial Fact:
Sales to customers (Note 9): 17.82B
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.68, $0.03 better than the analyst estimate of $1.65. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.71 billion.
Xarelto revenue $529 million, versus $564 million expected.
Imbruvica revenue $349 million, estimate at $313 million.
Guidance:
J&J now sees FY16 adjusted EPS of $6.68 - $6.73, versus an expected range of $6.63 - $6.73 prior and compared with the current consensus of $6.69. Sales guidance was maintained.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
- Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!